FTC Study On PBM Practices, Rebates: Stalemate So Far, But Bipartisan Interest Remains
After motion to advance fails at 17 February meeting, proposed study design will be revamped, not scrapped. Despite the 2-2 deadlock on the vote, commissioners uniformly expressed an interest in proceeding with research on PBM industry, focusing on the leading players.
You may also be interested in...
Pfizer’s acquisition of Arena without FTC intervention and Hikma’s acquisition of Custopharm with one product divestiture shows the commission is bound by anticompetitive facts of a deal. A more controversial merger may not get through, former FTC attorney says.
As they revise and interpret merger guidelines, the Federal Trade Commission and Department of Justice should pay particular attention to the anticompetitive impact of consolidation in the pharmacy benefit manager market, the generic trade group suggests.
With formal study still stalled, the information collection will enable FTC to examine a ‘wide array’ of pharmacy benefit manager business practices impacting patients, payers and pharmacies.